

University of Dundee

The role of pulmonary arterial stiffness in COPD

Weir-McCall, Jonathan R.; Struthers, Allan D.; Lipworth, Brian J.; Houston, J. Graeme

Published in:
Respiratory Medicine

DOI:
[10.1016/j.rmed.2015.06.005](https://doi.org/10.1016/j.rmed.2015.06.005)

Publication date:
2015

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Weir-McCall, J. R., Struthers, A. D., Lipworth, B. J., & Houston, J. G. (2015). The role of pulmonary arterial stiffness in COPD. *Respiratory Medicine*, 109(11), 1381-1390. <https://doi.org/10.1016/j.rmed.2015.06.005>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Review article

The role of pulmonary arterial stiffness in COPD

Jonathan R. Weir-McCall^{a,*}, Allan D. Struthers^a, Brian J. Lipworth^b, J. Graeme Houston^a^a Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, United Kingdom^b Scottish Centre for Respiratory Research, Medical Research Institute, University of Dundee, Dundee, United Kingdom

ARTICLE INFO

Article history:

Received 10 January 2015

Received in revised form

10 May 2015

Accepted 10 June 2015

Available online 12 June 2015

Keywords:

Pulmonary disease

Chronic obstructive

Hypertension

Pulmonary

Vascular capacitance

Vascular resistance

Pulmonary heart disease

ABSTRACT

COPD is the second most common cause of pulmonary hypertension, and is a common complication of severe COPD with significant implications for both quality of life and mortality. However, the use of a rigid diagnostic threshold of a mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg when considering the impact of the pulmonary vasculature on symptoms and disease is misleading. Even minimal exertion causes oxygen desaturation and elevations in mPAP, with right ventricular hypertrophy and dilatation present in patients with mild to moderate COPD with pressures below the threshold for diagnosis of pulmonary hypertension. This has significant implications, with right ventricular dysfunction associated with poorer exercise capability and increased mortality independent of pulmonary function tests.

The compliance of the pulmonary artery (PA) is a key component in decoupling the right ventricle from the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the microcirculation from large pressure gradients. PA stiffness increases with the severity of COPD, and correlates well with the presence of exercise induced pulmonary hypertension. A curvilinear relationship exists between PA distensibility and mPAP and pulmonary vascular resistance (PVR) with marked loss of distensibility before a rapid rise in mPAP and PVR occurs with resultant right ventricular failure. This combination of features suggests PA stiffness as a promising biomarker for early detection of pulmonary vascular disease, and to play a role in right ventricular failure in COPD. Early detection would open this up as a potential therapeutic target before end stage arterial remodelling occurs.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Contents

1. Introduction	1381
1.1. Vascular changes	1382
1.1.1. The right ventriculo-arterial model	1382
1.1.2. Measuring pulmonary artery stiffness	1384
1.1.3. Pulmonary arterial stiffness as a treatment target	1385
2. Conclusions	1386
Acknowledgements: Funding, disclosures	1386
References	1386

1. Introduction

COPD is the second most common cause of pulmonary hypertension after left sided heart disease [1]. Pulmonary hypertension

(Cor Pulmonale when associated with right heart failure in COPD) is relatively common in severe COPD and is present in >50% of patients awaiting lung transplantation [2]. The incidence increases with increasing severity of COPD, with pulmonary hypertension present in 5% of moderate (GOLD stage II), 27% of severe (GOLD stage III) and 53% of very severe (GOLD stage IV) COPD [3]. The true incidence in mild to moderate COPD however is poorly appreciated due to the absence of large scale epidemiological studies [4]. In

* Corresponding author. Division of Cardiovascular and diabetic medicine, Ninewells Hospital, Dundee DD1 9SY, United Kingdom.

E-mail address: j.weirmccall@dundee.ac.uk (J.R. Weir-McCall).

comparison to other causes of pulmonary hypertension the pulmonary pressure elevations are modest, however survival is poor and correlates better with the pulmonary pressures and pulmonary vascular resistance than with the severity of airflow obstruction [5–8].

Pulmonary hypertension is defined as a mean pulmonary arterial pressure (mPAP) greater than or equal to 25 mmHg at rest [9]. However: Pulmonary vascular changes occur in mild COPD before pulmonary hypertension occurs [10]; Right ventricular dysfunction has been observed in normoxaemic COPD patients with normal pulmonary arterial pressures [11]; and right ventricular hypertrophy is one of the earliest cardiac changes and is present even in mild COPD [12–14]. Additionally in both mice and guinea pig models, vascular remodelling occurs even before the onset of emphysema [15–17]. The notion of an elevated rest pressure as a cut-off is also restrictive in evaluating the role of the pulmonary arteries and right heart as even minimal exertion causes marked elevations in mPAP and oxygen desaturation in COPD, with exercise induced pulmonary hypertension present in 35%–58% of patients with normoxaemia or mild hypoxia [5,18–20].

Therefore the pulmonary hypertension model, whereby right ventricular failure occurs once pulmonary hypertension exists, is a misnomer, and an alternate should be considered – the right ventriculo-arterial model.

1.1. Vascular changes

Vascular remodelling within COPD develops secondary to intimal hyperplasia, with muscularisation of the arterioles and with rather little change in the tunica media [21,22]. This hyperplasia is induced by proliferation of smooth muscle cells and the deposition of elastic and collagen fibres [23,24]. Originally hypoxia was held to be the driving force behind this remodelling, however similar arterial changes are present in smokers with and without COPD, and arterial changes can be observed in mild COPD when hypoxia is yet to develop [10,23,25]. The vascular remodelling in COPD is most likely due to endothelial dysfunction and apoptosis which in turn causes remodelling, capillary loss and small vessel thrombosis [26]. This is likely due to a combination of local inflammatory mediators released from the endothelial dysfunction in the adjacent pulmonary parenchyma, and direct effects from the inhaled cigarette smoke on the vascular endothelium [24,26]. However an experimental study by Ferrer et al. in guinea pig models shows hypoxia still plays a contributory role, as a hypoxic environment after cigarette exposure induced significantly greater changes in pulmonary arterial pressures and pulmonary vascular remodelling than cigarette smoking or hypoxia alone [17]. More recently the pulmonary vascular sympathetic nerves which control the pulmonary baroreceptor reflex originating at the pulmonary trunk has been proposed to be of significant importance in the development of pulmonary arterial hypertension [27]. This is evidenced by a rise in pulmonary arterial pressures and pulmonary vascular resistance (PVR) induced by stretching the branch pulmonary arteries [27–30]. In a single study by Chen et al. [31] on 21 patients with significant pulmonary hypertension despite maximum medical therapy, intravascular pulmonary artery denervation with cessation of medical therapy resulted in significant improvement in pulmonary pressures and exercise capacity. However the role of this reflex in humans is still controversial and has also yet to be evaluated in COPD induced pulmonary hypertension [32].

1.1.1. The right ventriculo-arterial model

1.1.1.1. Right ventricle. The right ventricle (RV) got off to an inauspicious start in the 1940s and 50s when a series of papers showed

no significant alterations in the pulmonary arterial or systemic pressures following open ablation of the right heart in a dog model, leading one of the authors to conclude that “a normal, contractile right ventricular wall is not necessary for the maintenance of a normal circulation” [33–35]. Despite this apparent swan song for a significant role of the right ventricle, a paper in 1982 demonstrated that the open pericardial model did not accurately represent the functional haemodynamics of the heart [36]. Goldstein et al. demonstrated that when the right coronary artery was infarcted within an intact pericardium there was a profound and rapid fall in left ventricular pressures due to a fall in left ventricular (LV) preload, equalisation of RV and LV pressures and elevated intrapericardial pressures which did not occur when they repeated their experiment after pericardiectomy. Thus there is a marked ventricular interdependence due to the shared pericardial compartment, shared interventricular septum and the dependence of the left heart preload on the output of the right [37–43].

Recent work has shown the importance of the right heart in health and disease. In health the right ventricle responds to exercise, obesity and traditional cardiovascular risk factors in a manner similar to, but independent of, the left ventricle [44–46]. A decreased RV mass is associated with an increased risk of developing dyspnoea, and an increased RV mass is associated with an increased risk of future congestive cardiac failure and cardiovascular mortality in a healthy population [47,48]. In patients with COPD, right ventricular remodelling is apparent even early in the disease with right ventricular hypertrophy and diastolic dysfunction present in mild and moderate COPD with systolic impairment occurring in severe COPD [12,13]. This has significant implications with right ventricular dysfunction associated with poorer exercise capabilities and increased mortality independent of pulmonary function tests [49,50].

1.1.1.2. Pulmonary artery. There has been a great deal of recent interest in systemic arterial stiffening in COPD due to the mechanistically plausible link this provides between COPD and the excess cardiovascular mortality associated with this condition [51]. In comparison to the systemic arterial circulation there are several key differences in the nature of the vascular tree between that of the pulmonary and systemic circulation. The pulmonary artery is a low pressure, high distensibility system which acts to transform the highly pulsatile right ventricular output into the near steady flow at the capillary level [52]. The distal pulmonary vascular bed is also comprised of highly distensible vessels that, through distension and recruitment of the microvascular bed, are able to accommodate large increases in volume such as during exercise. This response is the opposite of that experienced in the systemic circulation where exercise induces vasoconstriction in the majority of the vascular tree other than the vessels supplying the muscles. This inbuilt reserve means that resting pulmonary arterial pressures will only rise relatively late in a disease process when 60–70% of the bed is obstructed [53]. The peripheral distensibility of the vessels also differs from the systemic circulation where only the proximal arteries act as capacitance vessels, expanding and contracting with each beat of the heart, while the peripheral vessels are responsible for resistance. Due to the dual function of the vessels, there is an inverse relationship between the resistance and capacitance of the pulmonary circulation, with the product of the two (the resistance-compliance time constant) remains the same in both health and disease [54].

The pulmonary arteries and microcirculation have distinct effects on the right ventricular afterload which can be split into two key components – the steady component required to drive and maintain forward flow and the oscillatory component required to overcome the pulsatile component of flow. The steady component

is a function of peripheral vascular resistance whereas the oscillatory component is a function both proximal and distal pulmonary arterial stiffness [55]. Even in the healthy adult, 30% of the right ventricular output is spent on generating pulsations (compared with only 10% in the systemic circulation) [56]. This energy is considered wasted in terms of ventricular power output, but is crucial in acting as a blood reservoir and maintaining steady flow through the pulmonary tree [57]. As the pulmonary artery stiffens the oscillatory component of the workload increases, although remains as a constant of the total energy expenditure of the right ventricle [58,59]. As the artery stiffens it also starts to dilate and become less compliant, and the dilation of this in relation to the aorta has been shown to be a useful clinical marker in COPD, with a PA:aortic ratio >1 an independent predictor of future acute exacerbations, exercise capacity, pulmonary hypertension and mortality [60–63].

The compliance of the pulmonary artery is a key component in decoupling the right ventricle from the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the microcirculation from large pressure gradients [52,64]. Indeed the stiffness of the pulmonary artery is a strong determinant of right ventricular function [65], and increased stiffness causes distal pulmonary arterial endothelial dysfunction and inflammation [66,67]. Increased stiffness is independently associated with reduced functional capacity [68], and higher mortality than the pulmonary artery pressures or pulmonary vascular resistance [69–73]. While vascular distensibility is partly dependant on underlying distending pressures [74,75], multiple studies have shown the intrinsic stiffness of the arterial walls to be increased in pulmonary hypertension independently of these [76–80].

1.1.1.3. Right ventriculo-arterial model. Optimal ventriculo-arterial coupling occurs when there is maximal transference of potential energy from one elastic chamber to another, e.g. from the ventricle to the artery. This is dependent on the elastance – the change in pressure for a given change in volume – of the two chambers [81]. The ventricular elastance (E_{ES}) is a load independent measure of the ventricular contractility combined with the modulating effects of the geometric and structural properties of the ventricle [82]. It relies on measuring the response of the ventricular pressure to increasing volumes (see Fig. 1). The arterial elastance (E_A) is an

index incorporating the elements affecting arterial load including pulmonary vascular resistance, arterial compliance, characteristic impedance, and systolic and diastolic time interval [83,84]. The E_A/E_{ES} calculates the extent of ventriculo-arterial coupling.

At rest the ventricle and pulmonary artery are coupled so that the right ventricle is working at optimal efficiency which occurs when the stroke work is maximal with minimal oxygen consumption [55,85–87]. This has been shown to occur when E_A is half E_{ES} [87–89]. In exercise this moves towards optimal coupling when there is maximal cardiac efficiency which is where there is maximum flow generation with minimal energy loss ($E_A = E_{ES}$) [90–92]. Interestingly the optimal values for energy efficiency and cardiac efficiency are similar throughout a variety of studied mammals suggesting it has been conserved throughout mammalian evolution [93,94]. During exercise, arterial stiffness has a progressively and intensity-dependant greater impact on E_A than PVR with the result that E_A increases on exercise despite a fall in PVR in a manner paralleling the rise in arterial stiffness [95–97]. A similar relationship is present in pulmonary hypertension whereby pulmonary stiffness has a 1.2–18 fold greater contribution to right ventricular workload than PVR [74,76,54]. In the systemic circulation, age and hypertension (two known factors associated with increased arterial stiffness) result in an exaggerated increase in E_A during exercise increasing the pulsatile load on the heart and in turn decreasing left ventricular efficiency [90,98]. This exaggerated response secondary to arterial stiffening may explain the rapid rise in mPAP observed in COPD during exercise despite a stable or minimal rise in PVR [18]. Indeed in a study by Hilde et al., an increase in pulmonary arterial stiffness was observed during exercise with a greater contribution from this to changes in mPAP than PVR [3]. Further indirect evidence comes from a study by Kubo et al. which showed the pulmonary arterial wall thickness to be related to exercise pulmonary pressures rather than resting pulmonary pressures, and to correlate highly with change in pressure from rest to exercise [99].

When the E_A increases so that the $E_A:E_{ES}$ is consistently above 0.5 the ventricle adapts to the increased workload by inducing hypertrophy [101]. This increases the E_{ES} thereby returning the ventriculo-arterial system to its most energy efficient state, albeit at a slightly higher energy consumption than previously [102–104]. As E_A continues to rise the right ventricle eventually fails to adapt with a resultant decrease in the E_{ES} and thereby a rapid increase in E_A/E_{ES} indicating uncoupling and reduced myocardial efficiency [87,105].

Fourie et al. demonstrated that myocardial efficiency reached a maximum when the E_A reached 1 mmHg ml^{-1} (corresponding to an mPAP of 20 mmHg), while maximum stroke work corresponded to an E_A of 2 mmHg ml^{-1} (corresponding to a MPAP of 30–40 mmHg) [52]. This corresponds with observations that at approximately 40 mmHg the pulmonary artery reaches its maximum dimension and minimal distensibility [78,105,106]. Consistent with this, Stevens et al. demonstrated that in patients with pulmonary hypertension there was a curvilinear relationship between RV function and PA distensibility with marked loss of pulmonary artery distensibility without commensurate loss of ventricular function until only minimal distensibility remained when a rapid decompensation of the right ventricle occurred [76]. A similar curvilinear relationship has also been observed in COPD between pulmonary arterial stiffness and peripheral vascular resistance, with a rapid rise in PVR only occurring after significant stiffening of the pulmonary arteries has occurred [11]. Pulmonary stiffness is increased early in pulmonary hypertension development, and is increased even in those with exercise induced pulmonary hypertension, both in mixed pulmonary arterial hypertension studies and in COPD [3,11,78,106]. This combination of features suggest pulmonary




Fig. 1. Calculation of $E_A:E_{ES}$ in the right ventricle and pulmonary artery. Ventricular end systolic pressure-volume is linear and characterised by the slope E_{ES} and is generated by measuring pressure-volume loops under graded preload and afterload conditions. Reproduced from Wang et al., 2011 [100]. E_A = Arterial elastance; E_{ES} = Ventricular elastance.

Table 1

Measures of arterial stiffness – Calculations, definitions and alternate means of assessment.

	Calculation	Definition	Method of assessment
Local			
Pulsatility (%)	$(\max A - \min A) / \min A \times 100$	Relative change in lumen area during the cardiac cycle	MRI Echocardiography IVUS
Compliance (mm^2/mmHg)	$(\max A - \min A) / \text{PP}$	Absolute change in lumen area for a given change in pressure	RHC plus MRI/Echo/IVUS
Distensibility ($\%/ \text{mmHg}$)	$[(\max A - \min A) / \text{PP} \times \min A] \times 100$	Relative change in lumen area for a given change in pressure	RHC plus MRI/Echo/IVUS
Elastic modulus (mmHg)	$\text{PP} \times \min A / (\max A - \min A)$	Pressure change driving a relative increase in lumen area	RHC plus MRI/Echo/IVUS
Stiffness index (N/A)	$\text{Ln}(\text{sPAP}/\text{dPAP}) / [(\max A - \min A) / \min A]$	Slope of the function between distending arterial pressure and arterial distension	RHC plus MRI/Echo/IVUS
Young's elastic modulus	$[3(1 + \min A / \text{WCSA})] / \text{Distensibility}$	Wall thickness for a given distensibility	RHC plus IVUS
Regional			
Capacitance (mm^3/mmHg)	SV / PP	Change in volume associated with a given change in pressure	RHC
PWV (ms^{-1})	$\Delta d / \Delta t$ (TT technique) $\Delta Q / \Delta A$ (Flow-area technique)	Speed of transmission of pressure wave	RHC MRI
Systemic			
Elastance (mmHgml^{-1})	$E_A / E_{ES} = (\text{ESP} / \text{SV}) / (\text{ESP} / \text{ESV} - \text{V}_0)$	Change in pressure for a given change in volume	RHC with flow-volume loops

A = area; d = distance; dPAP = diastolic pulmonary artery pressure; EA = Arterial elastance; Echo = echocardiography; EES = Ventricular elastance; IVUS = intravascular ultrasound; maxA = maximum cross sectional area; minA = minimum cross sectional area; MRI = magnetic resonance imaging; PP = pulse pressure; PWV = pulse wave velocity; Q = Flow over a single heart beat; RHC = right heart catheter; sPAP = systolic pulmonary artery pressure; SV = stroke volume; t = time; WCSA = Wall cross sectional area.

arterial stiffness as a promising biomarker for detection of early disease and as a potential therapeutic target before end stage arterial remodelling occurs with dire consequences for the right ventricle.

1.1.2. Measuring pulmonary artery stiffness

The stiffness of the pulmonary artery can be quantified using a variety of metrics, with these measuring stiffness locally, regionally or systemically. Table 1 summarises the various methods of measuring arterial stiffness and the common methods for acquiring these. As can be seen from the table the majority of these require knowledge of the arterial pressures to calculate the stiffness. In the arterial circulation this is not a significant issue as the brachial arterial pressures are readily obtained with a sphygmomanometer, as mean BP and diastolic BP are relatively constant throughout the large arteries [107]. However in the pulmonary arteries this provides a significant hurdle as an external measurement of the pressures is not readily available. Despite numerous attempts to quantify pulmonary arterial pressures and vascular resistance using

echocardiography, CT and MRI, none of these have yet proven accurate enough to negate the need for invasive measurement with right heart catheterisation [108–115].

1.1.2.1. Right heart catheterisation. Right heart catheterisation can be used to calculate several metrics of arterial stiffness, including capacitance, PWV and elastance, although the latter two require dedicated catheters and equipment not routinely available in the catheter laboratory. In addition, it can be combined with techniques for the visualisation of the pulmonary artery cross sectional area such as MRI or intravascular ultrasound, to derive a wide range of metrics of arterial stiffness and ventriculo-arterial coupling. Table 2 summarises the studies looking at invasive assessment of pulmonary arterial stiffness. Despite its utility, RHC has numerous disincentives including its invasive nature, cost, and exposure to ionising radiation. While the combination of MRI and right heart catheterisation allows catheter guidance without exposure to ionising radiation and simultaneous acquisition of anatomical and pressure measurements, it does not negate the invasive or costly nature of

Table 2

Summary of studies looking at invasive measurement of pulmonary arterial stiffness.

Study	Population	No	Method	Finding
Milnor et al. [118]	Mixed PH	7	RHC	Increased impedance in PH
Nakayama et al. [119]	Mixed PH	62	RHC	Increased augmentation index and earlier inflection time in PH
Castelain et al. [77]	Mixed PH	14	RHC	Increased augmentation index and earlier inflection time in PH
Mahapatra et al. [70]	Mixed PH	104	RHC	Capacitance strongest predictor of mortality in PH. On multivariate analysis, capacitance was the only statistically significant predictor of mortality.
Hilde et al. [11] ^a	COPD	98	RHC	PA compliance greatly reduced in COPD Gold 2,3 and 4
Hilde et al. [3] ^a	COPD	98	RHC	PA compliance fell with exercise in patients with and without PH, with similar elevations in mPAP during exercise between the two groups.
Muthurangu et al. [120]	IPAH	17	RHC with MRI	Inverse relationship between compliance and PVRI and mPAP. A fall in compliance was evident in 7/17 following nitric oxide inhalation
Kuehne et al. [87]	Mixed	12	RHC with MRI	Increased elastance in PH, with resultant ventriculo-arterial uncoupling
Kopeck et al. [121]	IPAH	26	RHC with IVUS	PWV high in IPAH (mean PWV 10 ms^{-1}) with excellent correlation with compliance ($\beta = -0.81$) and reasonable correlation with mPAP ($\beta = 0.48$)
Lau et al., 2012 [79]	IPAH	8	RHC with IVUS	Increase in all measure of pulmonary arterial stiffness. Inverse curvilinear relationship between mPAP and compliance and distensibility. No change in PA stiffness following 6 months of bosentan therapy.
Rodes-Cabau et al. [72]	IPAH	20	RHC with IVUS	Reduced pulsatility in PH, with reduced pulsatility predictive of future mortality. Epoprostenol infusion increased pulsatility by 53%.
Lau et al., 2014 [122]	IPAH	5	RHC with IVUS	High PWV in IPAH (mean PWV 10.6 ms^{-1}) with the reflected backward compression wave carrying 31% of the energy of the forward compression wave

COPD = chronic obstructive pulmonary disease; CoV = Coefficient of variation; EIPH = Exercise induced pulmonary hypertension; FEV1 = Forced expiratory volume in 1 s; HV = Healthy volunteers; IPAH = Idiopathic pulmonary arterial hypertension; NYHA = New York heart association; PAsP = Pulmonary artery systolic pressure; PH = Pulmonary hypertension; PWV = pulse wave velocity; QA = flow by area; TT = transition time; 6MWT = 6 min walking test.

^a Drawn from the same population.

the study [116,117]. Of the measures of arterial stiffness, only pulsatility and pulse wave velocity can be derived entirely non-invasively.

1.1.2.2. Pulsatility. Multiple studies have shown reduced pulsatility in pulmonary hypertension, [68,69,80,106,123–125]. A single echocardiography study has shown reduced pulmonary artery pulsatility in COPD, which correlated with right ventricular functional parameters [126]. A single abstract using cardiac MR has also described decreasing pulsatility with increasing severity of COPD [127] (Table 3). However, as discussed above, the pulmonary stiffness is dependant not only upon distending pressures, but also upon the intrinsic elasticity of the pulmonary vessel wall, thus a fall in pulmonary pulsatility does not differentiate a fall in pulsatility due to a fall in stroke volume or in distending pressures from that of a rise in arterial stiffness.

1.1.2.3. Pulse wave velocity. Pulse wave velocity (PWV) is the speed at which the pressure wave, generated by ventricular contraction, is transmitted through the arterial tree. This is directly related to vessel wall elasticity, with increased stiffness leading to increased PWV [128]. A reflected pressure wave is present which is generated when the pressure wave is reflected from the termination of the arteries, with alterations in the smallest arteries increasing the size of the reflected wave while large artery stiffening increases the PWV [118]. In health this reflected wave only represents a tiny fraction of the total output energy, and arrives in diastole and reduces preload of the subsequent ventricular contraction [92,118,129,130]. However in pulmonary hypertension this can reach 30% of the forward wave energy, with an increased PWV resulting in the earlier arrival of the reflected wave during systole thereby increasing the afterload of the heart and thus cardiac workload [77,119,122,131–133].

PWV is an established marker of arterial stiffness in the systemic circulation with aortic pulse wave velocity shown to be associated with future cardiovascular events, and to improve risk stratification [134]. Transcutaneous waveform analysis methods are the gold standard for aortic PWV measurement including pressure [135], distension [136], and flow waveform [137]. However a transcutaneous approach is not possible for the pulmonary arteries. While PWV can be measured invasively on right heart catheterisation [118], magnetic resonance imaging is a possible alternative for non-invasive assessment of the pulmonary arteries using flow waveforms [138]. It is performed by the acquisition of ECG gated phase contrast sequences which measure flow the in proximal main pulmonary artery and in the mid right or left pulmonary arteries. A distance can be calculated between the two imaging planes (Fig. 2), and the pulse wave timed from when it leaves the main pulmonary artery until it arrives in branch pulmonary arteries thus allowing a speed between the two points to be generated [138]. MRI derived pulse wave velocity has been previously validated against both invasive and non-invasive techniques in the aorta [139–141]. Several studies have shown this to be a feasible and reproducible technique in the pulmonary arteries in healthy volunteers [138,142], with the observed pulse wave velocity of 1.96–2.3 ms⁻¹ similar to that obtained invasively [118,129]. Pulse wave velocity is raised in pulmonary hypertension on both invasive and MRI assessment (See Table 2) [121,143]. To date there have been no studies assessing pulmonary PWV in COPD.

1.1.3. Pulmonary arterial stiffness as a treatment target

Traditional treatments of pulmonary hypertension such as phosphodiesterase inhibitors and endothelin-1 receptor antagonists have yielded disappointing results despite their success in treating pulmonary hypertension, primarily due to worsening ventilatory-perfusion mismatches [144–148]. However these treatments have all focussed on altering the peripheral vasculature.

Table 3
Summary of studies looking at non-invasive measurement of pulmonary arterial stiffness.

Study	Population	No	Method	Finding
Pulsatility				
Bogren et al. [159] ^b	Mixed PH	4	MRI	Pulsatility 23% in HV and 8% in PH
Paz et al. [160]	HV	9	MRI	No difference in pulsatility between the main pulmonary artery, right pulmonary artery and left pulmonary arteries.
Gan et al. [69]	Suspected PH	70	MRI	Right pulmonary artery pulsatility showed a curvilinear relationship with mortality. Pulsatility <16%
Jardim et al. [125] ^b	IPAH	19	MRI	<10% pulsatility predicts non-responders to acute vasodilator testing with 100% sens and 56% spec.
Sanz et al. [124] ^a	Suspected PH	59	MRI	Pulsatility 41% in non-PH and 17.4% in PH. No difference in pulsatility between different causes of PH.
Sanz et al. [78] ^a	Suspected PH	94	MRI	No difference in pulsatility between group without PH and EIPH. Pulsatility <40% predicted PH with 93% sens. and 63% spec.
Kang et al. [68]	Mixed PH	35	MRI	Pulsatility correlated with 6MWT (R ² = 0.61, p < 0.001) <20% pulsatility predicted poor function (6MWT <400m) with 82% sens. and 94% spec.
Stevens et al. [76] ^a	Suspected PH	124	MRI	Pulsatility correlates with right ventricular function
Stevens et al. [161]	Suspected PH	43	MRI	Pulsatility correlated with exercise capacity while RHC pressures did not.
Swift et al. [106]	Suspected PH	134	MRI	Pulsatility elevated even in very mild elevations in PVR. Pulsatility predicted mortality.
Revel et al. [162] ^b	Suspected PH	45	CT	Pulsatility of 16.5% predicted PH with sens 86% and spec 96%.
Pasierski et al. [80]	Suspected PH	19	Echo	Pulsatility reduced in pulmonary hypertension with a linear relationship between pulsatility and PASP
Mahapatra et al. [71]	Suspected PH	54	Echo	Capacitance was the strongest predictor of mortality including invasive pressure measurements
Ertan et al. [126]	COPD	54	Echo	Right pulmonary artery pulsatility reduced in COPD patients, with significant differences between NYHA functional classes.
Liu et al. [127]	COPD	135	MRI	Pulsatility falls with increasing severity of COPD, with a positive association with %predicted FEV1 and inversely correlated with %emphysema
PWV				
Peng et al. [142]	HV	17	MRI	PWV 1.96 ± 0.27 with high intra-scan and inter-scan reproducibility (5.5% and –10.9% respectively)
Bradlow et al. [138]	HV	10	MRI	No significant difference in PWV using the left or right pulmonary arteries. CoV 12% for both intra and inter-observer assessment.
Ibrahim et al. [143]	Heterogeneous	33	MRI	PWV raised in pulmonary hypertension. Comparable measurements between TT and QA methods.

COPD = chronic obstructive pulmonary disease; CoV = Coefficient of variation; EIPH = Exercise induced pulmonary hypertension; FEV1 = Forced expiratory volume in 1 s; HV = Healthy volunteers; IPAH = Idiopathic pulmonary arterial hypertension; NYHA = New York heart association; PASP = Pulmonary artery systolic pressure; PH = Pulmonary hypertension; PWV = pulse wave velocity; QA = flow by area; TT = transition time; 6MWT = 6 min walking test.

^a Drawn from the same population.

^b Different calculation for % pulsatility so not directly comparable to other studies.




Fig. 2. Measurement of PWV using MRI: The location of the two phase contrast planes are delineated on the left image with the distance between them measured. The two separate waveforms are traced on the right relative to the triggering R-wave used to start image acquisition. The time between the waves arriving at the two consecutive locations can then be measured allowing calculation of the speed of the pulse wave.

Given the greater impact of pulmonary stiffness on remodelling, drugs to target and ameliorate this process may be a novel route to target. Due to the relatively recent identification of the importance of pulmonary arterial stiffness in right ventricular remodelling, there have been relatively few studies targeted at its treatment. Despite this there are several studies suggestive of promising avenues for further exploration.

Statins have been proposed as a route to reduce systemic arterial stiffness [149], although a meta-analysis showed mixed response with two studies showing improvement, one showing no change and another showing progression of stiffening [150]. Statins in guinea pigs and mice with emphysema have been shown to reverse arterial remodelling and halt the formation of emphysema [151,152]. Indirect evidence of the benefits from statins in COPD related pulmonary hypertension come from observational studies showing lower pulmonary arterial pressures in patients on statins prior to right heart catheterisation [153]. Furthermore a study on pulmonary arterial stiffness showed that other than mPAP, the only other factors independently associated with pulmonary arterial stiffness was LDL cholesterol and BMI [121]. Statins are also associated with increased exercise capacity and reduced mortality in COPD [154–156], however due to the observational nature of these studies the underpinning mechanisms are still in debate [157,158].

Xanthine oxidase inhibitors have been shown to improve endothelial function and arterial stiffness in the systemic circulation [163–167]. They have also been shown to reduce endothelial dysfunction induced by smoking and obstructive sleep apnoea [168–170] – a condition similar to COPD in its effects of intermittent hypoxia [171]. Additionally allopurinol inhibits hypoxia induced pulmonary vasoconstriction, pulmonary hypertension, endothelial dysfunction and vascular remodelling in hypoxic animal models of pulmonary hypertension [172–176]. It has been shown to reduce airway reactive nitrogen species production in COPD, however its effects on smoking induced pulmonary vascular damage has not been assessed [177].

As with xanthine oxidase inhibitors, mineralocorticoid receptor antagonists have been shown to improve systemic endothelial function and arterial stiffness [178–180]. In 2 separate mouse models of pulmonary hypertension, mineralocorticoid receptor antagonists prevented or reversed adverse pulmonary vascular remodelling with improved pulmonary vascular resistance, pulmonary artery pressure, and remodelling of the right ventricle [181]. A group in Bethesda, USA are currently recruiting patients

with pulmonary hypertension without right heart failure to evaluate its efficacy in humans in modulating pulmonary vascular remodelling [182]. Its use in COPD has not currently been assessed.

Long term oxygen therapy improves survival in severe COPD and reduces pulmonary arterial pressures and vascular resistance while improving cardiac output [6,183]. It has also been shown to reduce peripheral arterial stiffness in COPD, however its effects on the pulmonary arterial stiffness has not been evaluated [184].

There are also several new classes of pharmaceutical agents currently being designed which specifically target the processes causing arterial stiffening. Currently these are all being targeted at systemic vascular remodelling and are in the pre-clinical stages, however should they prove successful at preventing or reversing systemic arterial remodelling they would be promising agents for evaluation in pulmonary remodelling. The most promising of these are TGF-B1 antagonists, and drugs targeting the advanced glycation end products (AGEs) [185]. TGF-B1 is responsible for extracellular matrix remodelling and vascular fibrosis in chronic inflammatory conditions, whilst AGE form irreversible cross-links with collagen and elastin, reducing the elasticity of the arterial wall [185].

2. Conclusions

Pulmonary arterial stiffness holds a crucial role in right ventricular dysfunction in pulmonary hypertension, and demonstrates promise as a useful biomarker in the development of this disease. Early work shows similar promise in COPD, and further work is warranted to explore this promising new area.

Acknowledgements: Funding, disclosures

JRW is supported by the Wellcome Trust through the Scottish Translational Medicine and Therapeutics Initiative (Grant no. WT 085664) in the form of a Clinical Research Fellowship. The funder had no role in study design, the collection, analysis, and interpretation of data; in the writing of the manuscript; nor in the decision to submit the manuscript for publication.

References

- [1] A. Hyduk, J.B. Croft, C. Ayala, K. Zheng, Z.-J. Zheng, G.A. Mensah, Pulmonary hypertension surveillance—United States, 1980–2002, *MMWR Surveill. Summ.* 54 (2005) 1–28.

- [2] G. Thabut, G. Dauriat, J.B. Stern, D. Logeart, A. Lévy, R. Marrash-Chahla, et al., Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation, *Chest* 127 (2005) 1531–1536.
- [3] J.M. Hilde, I. Skjorten, V. Hansteen, M.N. Melsom, J. Hisdal, S. Humerfelt, et al., Haemodynamic responses to exercise in patients with COPD, *Eur. Respir. J.* 41 (2013) 1031–1041.
- [4] O.A. Minai, A. Chaouat, S. Adnot, Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective, *Chest* 137 (2010) 395–515.
- [5] R. Kessler, M. Faller, E. Weitzenblum, A. Chaouat, A. Aykut, A. Ducolone, et al., “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease, *Am. J. Respir. Crit. Care Med.* 164 (2001) 219–224.
- [6] M. Oswald-Mammossier, E. Weitzenblum, E. Quoix, G. Moser, A. Chaouat, C. Charpentier, et al., Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure, *Chest* 107 (1995) 1193–1198.
- [7] E. Weitzenblum, C. Hirth, A. Ducolone, R. Mirhom, J. Rasaholjanahary, M. Ehrhart, Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease, *Thorax* 36 (1981) 752–758.
- [8] M.J. Cuttica, R. Kalhan, O.A. Shlobin, S. Ahmad, M. Gladwin, R.F. Machado, et al., Categorization and impact of pulmonary hypertension in patients with advanced COPD, *Respir. Med.* 104 (2010) 1877–1882.
- [9] N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J.A. Barbera, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Internat, *Eur. Heart J.* 30 (2009) 2493–2537.
- [10] V.I. Peinado, J.A. Barbera, P. Abate, J. Ramirez, J. Roca, S. Santos, et al., Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease, *Am. J. Respir. Crit. Care Med.* 159 (1999) 1605–1611.
- [11] J.M. Hilde, I. Skjorten, O.J. Grøtta, V. Hansteen, M.N. Melsom, J. Hisdal, et al., Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension, *J. Am. Coll. Cardiol.* 62 (2013) 1103–1111.
- [12] A. Vonk-Noordegraaf, J.T. Marcus, S. Holverda, B. Roseboom, P.E. Postmus, Early changes of cardiac structure and function in COPD patients with mild hypoxemia, *Chest* 127 (2005) 1898–1903.
- [13] Y. Gao, X. Du, W. Qin, K. Li, Assessment of the right ventricular function in patients with chronic obstructive pulmonary disease using MRI, *Acta Radiol.* 52 (2011) 711–715.
- [14] P.M. Pattynama, L.N. Willems, A.H. Smit, E.E. van der Wall, A. de Roos, Early diagnosis of cor pulmonale with MR imaging of the right ventricle, *Radiology* 182 (1992) 375–379.
- [15] M. Seimetz, N. Parajuli, A. Pichl, F. Veit, G. Kwapiszewska, F.C. Weisel, et al., Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice, *Cell* 147 (2011) 293–305.
- [16] J.L. Wright, A. Churg, Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig, *Exp. Lung Res.* 17 (1991) 997–1009.
- [17] E. Ferrer, V.I. Peinado, J. Castañeda, J. Prieto-Lloret, E. Olea, M.C. González-Martín, et al., Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig, *Eur. Respir. J.* 38 (2011) 617–627.
- [18] S. Holverda, H. Rietema, N. Westerhof, J.T. Marcus, C.T.-J. Gan, P.E. Postmus, et al., Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by increased pulmonary artery pressure, *Heart* 95 (2009) 137–141.
- [19] C.C. Christensen, M.S. Ryg, A. Edvardsen, O.H. Skjongsberg, Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients, *Eur. Respir. J.* 24 (2004) 580–586.
- [20] I. Skjorten, J.M. Hilde, M.N. Melsom, V. Hansteen, K. Steine, S. Humerfelt, Pulmonary artery pressure and PaO₂ in chronic obstructive pulmonary disease, *Respir. Med.* 107 (2013) 1271–1279.
- [21] J.A. Barbera, A. Riverola, J. Roca, J. Ramirez, P.D. Wagner, D. Ros, et al., Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease, *Am. J. Respir. Crit. Care Med.* 149 (1994) 423–429.
- [22] F. Magee, J.L. Wright, B.R. Wiggs, P.D. Paré, J.C. Hogg, Pulmonary vascular structure and function in chronic obstructive pulmonary disease, *Thorax* 43 (1988) 183–189.
- [23] S. Santos, V.I. Peinado, J. Ramirez, T. Melgosa, J. Roca, R. Rodriguez-Roisin, et al., Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD, *Eur. Respir. J.* 19 (2002) 632–638.
- [24] J.A. Barbera, Mechanisms of development of chronic obstructive pulmonary disease-associated pulmonary hypertension, *Pulm. Circ.* 3 (2013) 160–164.
- [25] V.I. Peinado, J.A. Barbera, J. Ramirez, F.P. Gomez, J. Roca, L. Jover, et al., Endothelial dysfunction in pulmonary arteries of patients with mild COPD, *Am. J. Physiol.* 274 (1998) L908–L913.
- [26] N.F. Voelkel, J. Gomez-Arroyo, S. Mizuno, COPD/emphysema: the vascular story, *Pulm. Circ.* 1 (2013) 320–326.
- [27] S.-L. Chen, Y.-J. Zhang, L. Zhou, D.-J. Xie, F.-F. Zhang, H.-B. Jia, et al., Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo, *EuroIntervention* 9 (2013) 269–276.
- [28] B.G. Baylen, G.C. Emmanouilides, C.E. Juratsch, Y. Yoshida, W.J. French, J.M. Criley, Main pulmonary artery distention: a potential mechanism for acute pulmonary hypertension in the human newborn infant, *J. Pediatr.* 96 (1980) 540–544.
- [29] C.E. Juratsch, J.A. Jengo, J. Castagna, M.M. Laks, Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature, *Chest* 77 (1980) 525–530.
- [30] J. Osorio, M. Russek, Reflex changes on the pulmonary and systemic pressures elicited by stimulation of baroreceptors in the pulmonary artery, *Circ. Res.* 10 (1962) 664–667.
- [31] S.-L. Chen, F.-F. Zhang, J. Xu, D.-J. Xie, L. Zhou, T. Nguyen, et al., Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension), *J. Am. Coll. Cardiol.* 62 (2013) 1092–1100.
- [32] N. Galiè, A. Manes, New treatment strategies for pulmonary arterial hypertension: hopes or hypes? *J. Am. Coll. Cardiol.* 62 (2013) 1101–1102.
- [33] I. Starr, W.A. Jeffers Jr., R.H.M., The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease, *Am. Heart J.* 26 (1943) 291–301.
- [34] A.C.P. Bakos, The question of the function of the right ventricular myocardium: an experimental study, *Circulation* 1 (1950) 724–732.
- [35] A. Kagan, Dynamic responses of the right ventricle following extensive damage by cauterization, *Circulation* 5 (1952) 816–823.
- [36] J.A. Goldstein, G.J. Vlahakes, E.D. Verrier, N.B. Schiller, J.V. Tyberg, T.A. Ports, et al., The role of right ventricular systolic dysfunction and elevated intrapericardial pressure in the genesis of low output in experimental right ventricular infarction, *Circulation* 65 (1982) 513–522.
- [37] B.M. Smith, M.R. Prince, E.A. Hoffman, D.A. Bluemke, C.-Y. Liu, D. Rabinowitz, et al., Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The multi-ethnic study of atherosclerosis COPD Study, *Chest* 144 (2013) 1143–1151.
- [38] A. Vonk-Noordegraaf, J.T. Marcus, C.T. Gan, A. Boonstra, P.E. Postmus, Inter-ventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling, *Chest* 128 (2005) 628S–630S.
- [39] J.T. Marcus, C.T.-J. Gan, J.J.M. Zwanenburg, A. Boonstra, C.P. Allaart, M.J.W. Götte, et al., Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling, *J. Am. Coll. Cardiol.* 51 (2008) 750–757.
- [40] A. Vonk-Noordegraaf, J.T. Marcus, B. Roseboom, P.E. Postmus, T.J. Faes, P.M. de Vries, The effect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary emphysema, *Chest* 112 (1997) 640–645.
- [41] M.L. Shehata, A.A. Harouni, J. Skrok, T.A. Basha, D. Boyce, N. Lechtzin, et al., Regional and global biventricular function in pulmonary arterial hypertension: a cardiac MR imaging study, *Radiology* 266 (2013) 114–122.
- [42] M. Hardziyenka, M.E. Campian, H.J. Reesink, S. Surie, B.J. Bouma, M. Groenink, et al., Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: evidence for atrophic remodeling, *J. Am. Coll. Cardiol.* 57 (2011) 921–928.
- [43] A. Boussuges, C. Pinet, F. Molenat, H. Burnet, P. Ambrosi, M. Badier, et al., Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study, *Am. J. Respir. Crit. Care Med.* 162 (2000) 670–675.
- [44] C.P. Aaron, H. Tandri, R.G. Barr, W.C. Johnson, E. Bagiella, H. Chahal, et al., Physical activity and right ventricular structure and function. The MESA-right ventricle study, *Am. J. Respir. Crit. Care Med.* 183 (2011) 396–404.
- [45] H. Chahal, C. Johnson, H. Tandri, A. Jain, W.G. Hundley, R.G. Barr, et al., Relation of cardiovascular risk factors to right ventricular structure and function as determined by magnetic resonance imaging (results from the multi-ethnic study of atherosclerosis), *Am. J. Cardiol.* 106 (2010) 110–116.
- [46] H. Chahal, R.L. McClelland, H. Tandri, A. Jain, E.B. Turkbey, W.G. Hundley, et al., Obesity and right ventricular structure and function: the MESA-right ventricle study, *Chest* 141 (2012) 388–395.
- [47] M.R. Kaufmann, R.G. Barr, J.A.C. Lima, A. Praetstgaard, A. Jain, H. Tandri, et al., Right ventricular morphology and the onset of dyspnea: the MESA-right ventricle study, *PLoS One* 8 (2013) e56826.
- [48] S.M. Kawut, R.G. Barr, J.A.C. Lima, A. Praetstgaard, W.C. Johnson, H. Chahal, et al., Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the multi-ethnic study of atherosclerosis (MESA)–right ventricle study, *Circulation* 126 (2012) 1681–1688.
- [49] M.J. Cuttica, S.J. Shah, S.R. Rosenberg, R. Orr, L. Beussink, J.E. Dematte, et al., Right heart structural changes are independently associated with exercise capacity in non-severe COPD, *PLoS One* 6 (2011) e29069.
- [50] M.I. Burgess, N. Mogulkoc, R.J. Bright-Thomas, P. Bishop, J.J. Egan, S.G. Ray, Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease, *J. Am. Soc. Echocardiogr.* 15 (2002) 633–639.
- [51] I. Vivodtzev, R. Tamisier, J.-P. Baguet, J.C. Borel, P. Levy, J.-L. Pépin, Arterial stiffness in COPD, *Chest* 145 (2014) 861–875.

- [52] P.R. Fourie, A.R. Coetzee, C.T. Bolliger, Pulmonary artery compliance: its role in right ventricular-arterial coupling, *Cardiovasc Res.* 26 (1992) 839–844.
- [53] J.E. Dalen, F.W. Haynes Jr., F.G.H. Evans, P. Bhardwaj, L. Dexter, Cardiovascular responses to experimental pulmonary embolism, *Am. J. Cardiol.* 20 (1967) 3–9.
- [54] J.-W. Lankhaar, N. Westerhof, T.J.C. Faes, C.T.-J. Gan, K.M. Marques, A. Boonstra, et al., Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension, *Eur. Heart J.* 29 (2008) 1688–1695.
- [55] H. Piene, Pulmonary arterial impedance and right ventricular function, *Physiol. Rev.* 66 (1986) 606–652.
- [56] M.F. O'Rourke, Vascular impedance in studies of arterial and cardiac function, *Physiol. Rev.* 62 (1982) 570–623.
- [57] H. Piene, T. Sund, Flow and power output of right ventricle facing load with variable input impedance, *Am. J. Physiol.* 237 (1979) H125–H130.
- [58] D. Chemla, V. Castelain, K. Zhu, Y. Papelier, N. Creuze, S. Hoette, et al., Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension, *Chest* 143 (2013) 1343–1350.
- [59] N. Saouti, N. Westerhof, F. Helderma, J.T. Marcus, A. Boonstra, P.E. Postmus, et al., Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure, *Am. J. Respir. Crit. Care Med.* 182 (2010) 1315–1320.
- [60] S. Shin, C.S. King, A.W. Brown, M.C. Albano, M. Atkins, M.J. Sheridan, et al., Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease, *Respir. Med.* 108 (2014) 1626–1632.
- [61] J.M. Wells, G.R. Washko, M.K. Han, N. Abbas, H. Nath, A.J. Mamary, et al., Pulmonary arterial enlargement and acute exacerbations of COPD, *N. Engl. J. Med.* 367 (2012) 913–921.
- [62] A.S. Iyer, J.M. Wells, S. Vishin, S.P. Bhatt, K.M. Wille, M.T. Dransfield, CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD, *Chest* 145 (2014) 824–832.
- [63] J.M. Wells, A.S. Iyer, F.N. Rahaghi, S.P. Bhatt, H. Gupta, T.S. Denney, et al., pulmonary artery enlargement is associated with right ventricular dysfunction and loss of blood volume in small pulmonary vessels in chronic obstructive pulmonary disease, *Circ. Cardiovasc Imaging* 8 (2015) e002546–e002546.
- [64] M.E. Safar, B.I. Levy, H. Struijker-Boudier, Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases, *Circulation* 107 (2003) 2864–2869.
- [65] S. Gorgulu, M. Eren, N. Uslu, O. Ozer, Z. Nurkalem, The determinants of right ventricular function in patients with atrial septal defect, *Int. J. Cardiol.* 111 (2006) 127–130.
- [66] D. Scott, Y. Tan, R. Shandas, K.R. Stenmark, W. Tan, High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression, *Am. J. Physiol. Lung Cell. Mol. Physiol.* 304 (2013) L70–L81.
- [67] M. Li, D.E. Scott, R. Shandas, K.R. Stenmark, W. Tan, High pulsatility flow induces adhesion molecule and cytokine mRNA expression in distal pulmonary artery endothelial cells, *Ann. Biomed. Eng.* 37 (2009) 1082–1092.
- [68] K.-W. Kang, H.-J. Chang, Y.-J. Kim, B.-W. Choi, H.S. Lee, W.-I. Yang, et al., Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension, *Circ. J.* 75 (2011) 2244–2251.
- [69] C.T.-J. Gan, J.-W. Lankhaar, N. Westerhof, J.T. Marcus, A. Becker, J.W.R. Twisk, et al., Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension, *Chest* 132 (2007) 1906–1912.
- [70] S. Mahapatra, R.A. Nishimura, P. Sorajja, S. Cha, M.D. McGoon, Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension, *J. Am. Coll. Cardiol.* 47 (2006) 799–803.
- [71] S. Mahapatra, R.A. Nishimura, J.K. Oh, M.D. McGoon, The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension, *J. Am. Soc. Echocardiogr.* 19 (2006) 1045–1050.
- [72] J. Rodés-Cabau, E. Domingo, A. Román, J. Majó, B. Lara, F. Padilla, et al., Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension, *Heart* 89 (2003) 311–315.
- [73] M. Dupont, W. Mullens, H.N. Skouri, Z. Abrahams, Y. Wu, D.O. Taylor, et al., Prognostic role of pulmonary arterial capacitance in advanced heart failure, *Circ. Heart Fail* 5 (2012) 778–785.
- [74] J.-W. Lankhaar, N. Westerhof, T.J.C. Faes, K.M.J. Marques, J.T. Marcus, P.E. Postmus, et al., Quantification of right ventricular afterload in patients with and without pulmonary hypertension, *Am. J. Physiol. Heart Circ. Physiol.* 291 (2006) H1731–H1737.
- [75] B.D. Zuckerman, E.C. Orton, K.R. Stenmark, J.A. Trapp, J.R. Murphy, P.R. Coffeen, et al., Alteration of the pulsatile load in the high-altitude calf model of pulmonary hypertension, *J. Appl. Physiol.* 70 (1991) 859–868.
- [76] G.R. Stevens, A. Garcia-Alvarez, S. Sahni, M.J. Garcia, V. Fuster, J. Sanz, RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness, *JACC Cardiovasc Imaging* 5 (2012) 378–387.
- [77] V. Castelain, P. Hervé, Y. Lecarpentier, P. Duroux, G. Simonneau, D. Chemla, Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension, *J. Am. Coll. Cardiol.* 37 (2001) 1085–1092.
- [78] J. Sanz, M. Kariisa, S. Dellegrottaglie, S. Prat-González, M.J. Garcia, V. Fuster, et al., Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance, *JACC Cardiovasc Imaging* 2 (2009) 286–295.
- [79] E.M.T. Lau, N. Iyer, R. Ilisar, B.P. Bailey, M.R. Adams, D.S. Celmaj, Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound, *PLoS One* 7 (2012) e33331.
- [80] T.J. Pasierski, R.C. Starling, P.F. Binkley, A.C. Pearson, Echocardiographic evaluation of pulmonary artery distensibility, *Chest* 103 (1993) 1080–1083.
- [81] P.D. Chantler, E.G. Lakatta, S.S. Najjar, Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise, *J. Appl. Physiol.* 105 (2008) 1342–1351.
- [82] D.A. Kass, Age-related changes in ventricular-arterial coupling: pathophysiologic implications, *Heart Fail Rev.* 7 (2002) 51–62.
- [83] K. Sunagawa, W.L. Maughan, D. Burkoff, K. Sagawa, Left ventricular interaction with arterial load studied in isolated canine ventricle, *Am. J. Physiol.* 245 (1983) H773–H780.
- [84] R.P. Kelly, C.T. Ting, T.M. Yang, C.P. Liu, W.L. Maughan, M.S. Chang, et al., Effective arterial elastance as index of arterial vascular load in humans, *Circulation* 86 (1992) 513–521.
- [85] W.G. Kussmaul, A. Noordergraaf, W.K. Laskey, Right ventricular-pulmonary arterial interactions, *Ann. Biomed. Eng.* 20 (1992) 63–80.
- [86] E. Laffon, V. Bernard, M. Montaudon, R. Marthan, J.L. Barat, F. Laurent, Tuning of pulmonary arterial circulation evidenced by MR phase mapping in healthy volunteers, *J. Appl. Physiol.* 90 (2001) 469–474.
- [87] T. Kuehne, S. Yilmaz, P. Steendijk, P. Moore, M. Groenink, M. Saeed, et al., Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension, *Circulation* 110 (2004) 2010–2016.
- [88] D. Burkoff, K. Sagawa, Ventricular efficiency predicted by an analytical model, *Am. J. Physiol.* 250 (1986) R1021–R1027.
- [89] H. Suga, Y. Igarashi, O. Yamada, Y. Goto, Mechanical efficiency of the left ventricle as a function of preload, afterload, and contractility, *Heart Vessels* 1 (1985) 3–8.
- [90] S.S. Najjar, S.P. Schulman, G. Gerstenblith, J.L. Fleg, D.A. Kass, F. O'Connor, et al., Age and gender affect ventricular-vascular coupling during aerobic exercise, *J. Am. Coll. Cardiol.* 44 (2004) 611–617.
- [91] M.R. Starling, Left ventricular-arterial coupling relations in the normal human heart, *Am. Heart J.* 125 (1993) 1659–1666.
- [92] E.H. Hollander, J.J. Wang, G.M. Dobson, K.H. Parker, J.V. Tyberg, Negative wave reflections in pulmonary arteries, *Am. J. Physiol. Heart Circ. Physiol.* 281 (2001) H895–H902.
- [93] W.C. Little, C.P. Cheng, Left ventricular-arterial coupling in conscious dogs, *Am. J. Physiol.* 261 (1991) H70–H76.
- [94] G.J. Van den Horn, N. Westerhof, G. Elzinga, Optimal power generation by the left ventricle. A study in the anesthetized open thorax cat, *Circ. Res.* 56 (1985) 252–261.
- [95] T. Otsuki, S. Maeda, M. Iemitsu, Y. Saito, Y. Tanimura, R. Ajsaka, et al., Contribution of systemic arterial compliance and systemic vascular resistance to effective arterial elastance changes during exercise in humans, *Acta Physiol. (Oxf)* 188 (2006) 15–20.
- [96] T. Otsuki, S. Maeda, M. Iemitsu, Y. Saito, Y. Tanimura, R. Ajsaka, et al., Systemic arterial compliance, systemic vascular resistance, and effective arterial elastance during exercise in endurance-trained men, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 295 (2008) R228–R235.
- [97] S. Lalande, P. Yerly, V. Faoro, R. Naeije, Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals, *J. Physiol.* 590 (2012) 4279–4288.
- [98] S. Park, J.-W. Ha, C.Y. Shim, E.-Y. Choi, J.-M. Kim, J.-A. Ahn, et al., Gender-related difference in arterial elastance during exercise in patients with hypertension, *Hypertension* 51 (2008) 1163–1169.
- [99] K. Kubo, R.L. Ge, T. Koizumi, K. Fujimoto, T. Yamada, M. Haniuda, et al., Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema, *Respir. Physiol.* 120 (2000) 71–79.
- [100] Z. Wang, N.C. Chesler, Pulmonary vascular wall stiffness: an important contributor to the increased right ventricular afterload with pulmonary hypertension, *Pulm. Circ.* 1 (2011) 212–223.
- [101] C.A. Dias, R.S. Assad, L.F. Caneio, M.C.D. Abduch, V.D. Aiello, A.R. Dias, et al., Reversible pulmonary trunk banding. II. An experimental model for rapid pulmonary ventricular hypertrophy, *J. Thorac. Cardiovasc Surg.* 124 (2002) 999–1006.
- [102] A. Nitenberg, I. Antony, A. Loiseau, Left ventricular contractile performance, ventricular-arterial coupling, and left ventricular efficiency in hypertensive patients with left ventricular hypertrophy, *Am. J. Hypertens.* 11 (1998) 1188–1198.
- [103] A. Bellofiore, A. Roldán-Alzate, M. Besse, H.B. Kellihan, D.W. Consigny, C.J. Francois, et al., Impact of acute pulmonary embolization on arterial stiffening and right ventricular function in dogs, *Ann. Biomed. Eng.* 41 (2013) 195–204.
- [104] A. Nitenberg, A. Loiseau, I. Antony, Left ventricular mechanical efficiency in hypertensive patients with and without increased myocardial mass and with normal pump function, *Am. J. Hypertens.* 14 (2001) 1231–1238.

- [105] J. Sanz, A. García-Alvarez, L. Fernández-Friera, A. Nair, J.G. Mirelis, S.T. Sawit, et al., Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study, *Heart* 98 (2012) 238–243.
- [106] A.J. Swift, S. Rajaram, R. Condliffe, D. Capener, J. Hurdman, C. Elliot, et al., Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension, *Invest Radiol.* 47 (2012) 571–577.
- [107] E.J. Kroeker, E.H. Wood, Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man, *Circ. Res.* 3 (1955) 623–632.
- [108] E. Laffon, F. Laurent, V. Bernard, L. De Boucaud, D. Ducassou, R. Marthan, Noninvasive assessment of pulmonary arterial hypertension by MR phase-mapping method, *J. Appl. Physiol.* 90 (2001) 2197–2202.
- [109] G. Reiter, U. Reiter, G. Kovacs, B. Kainz, K. Schmidt, R. Maier, et al., Magnetic resonance-derived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure, *Circ. Cardiovasc Imaging* 1 (2008) 23–30.
- [110] T.S. Saba, J. Foster, M. Cockburn, M. Cowan, A.J. Peacock, Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure, *Eur. Respir. J.* 20 (2002) 1519–1524.
- [111] A.J. Swift, S. Rajaram, J. Hurdman, C. Hill, C. Davies, T.W. Sproson, et al., Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry, *JACC Cardiovasc Imaging* 6 (2013) 1036–1047.
- [112] R.J. Roelvelde, J.T. Marcus, A. Boonstra, P.E. Postmus, K.M. Marques, J.G.F. Bronzwaer, et al., A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension, *J. Magn. Reson Imaging* 22 (2005) 67–72.
- [113] M. Nogami, Y. Ohno, H. Koyama, A. Kono, D. Takenaka, T. Kataoka, et al., Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography, *J. Magn. Reson Imaging* 30 (2009) 973–980.
- [114] M.R. Fisher, P.R. Forfia, E. Chamara, T. Houston-Harris, H.C. Champion, R.E. Gargis, et al., Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension, *Am. J. Respir. Crit. Care Med.* 179 (2009) 615–621.
- [115] M. Pienn, G. Kovacs, M. Tscherner, A. Avian, T.R. Johnson, P. Kullnig, et al., Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study, *Eur. Radiol.* 24 (2014) 668–676.
- [116] V. Muthurangu, A. Taylor, R. Andriantsimiavona, S. Hegde, M.E. Miquel, R. Tulloh, et al., Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow, *Circulation* 110 (2004) 826–834.
- [117] T. Kuehne, S. Yilmaz, I. Schulze-Neick, E. Wellenhofer, P. Ewert, E. Nagel, et al., Magnetic resonance imaging guided catheterisation for assessment of pulmonary vascular resistance: in vivo validation and clinical application in patients with pulmonary hypertension, *Heart* 91 (2005) 1064–1069.
- [118] W.R. Milnor, C.R. Conti, K.B. Lewis, M.F. O'Rourke, Pulmonary arterial pulse wave velocity and impedance in man, *Circ. Res.* 25 (1969) 637–649.
- [119] Y. Nakayama, N. Nakanishi, T. Hayashi, N. Nagaya, F. Sakamaki, N. Satoh, et al., Pulmonary artery reflection for differentially diagnosing primary pulmonary hypertension and chronic pulmonary thromboembolism, *J. Am. Coll. Cardiol.* 38 (2001) 214–218.
- [120] V. Muthurangu, D. Atkinson, M. Sermesant, M.E. Miquel, S. Hegde, R. Johnson, et al., Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization, *Am. J. Physiol. Heart Circ. Physiol.* 289 (2005) H1301–H1306.
- [121] G. Kopeć, D. Moertl, P. Jankowski, A. Tyrka, B. Sobieć, P. Podolec, Pulmonary artery pulse wave velocity in idiopathic pulmonary arterial hypertension, *Can. J. Cardiol.* 29 (2013) 683–690.
- [122] E.M.T. Lau, D. Abelson, N. Dwyer, Y. Yu, M.K. Ng, D.S. Celermajer, Assessment of ventriculo-arterial interaction in pulmonary arterial hypertension using wave intensity analysis, *Eur. Respir. J.* 43 (2014) 1804–1807.
- [123] S. Moral, L. Fernández-Friera, G. Stevens, G. Guzman, A. García-Alvarez, A. Nair, et al., New index α improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices, *Int. J. Cardiol.* 161 (2012) 25–30.
- [124] J. Sanz, P. Kuschnir, T. Rius, R. Salguero, R. Sulica, A.J. Einstein, et al., Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging, *Radiology* 243 (2007) 70–79.
- [125] C. Jardim, C.E. Rochitte, M. Humbert, G. Rubinfeld, D. Jasinowodolinski, C.R.R. Carvalho, et al., Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study, *Eur. Respir. J.* 29 (2007) 476–481.
- [126] C. Ertan, N. Tarakci, O. Ozeke, A.D. Demir, Pulmonary artery distensibility in chronic obstructive pulmonary disease, *Echocardiography* 30 (2013) 940–944.
- [127] C.-Y. Liu, M. Parikh, A.S. Gomes, J. Vogel-Claussen, D.A. Bluemke, J.A. Lima, et al., Chronic obstructive pulmonary disease (COPD) is associated with pulmonary artery stiffness - the MESA COPD study, *J. Cardiovasc Magn. Reson* 15 (2013) O62.
- [128] E.-S.H. Ibrahim, K.R. Johnson, A.B. Miller, J.M. Shaffer, R.D. White, Measuring aortic pulse wave velocity using high-field cardiovascular magnetic resonance: comparison of techniques, *J. Cardiovasc Magn. Reson* 12 (2010) 26.
- [129] C.G. Caro, G.K. Harrison, Observations on pulse wave velocity and pulsatile blood pressure in the human pulmonary circulation, *Clin. Sci.* 23 (1962) 317–329.
- [130] N. Dwyer, A.C. Yong, D. Kilpatrick, Variable open-end wave reflection in the pulmonary arteries of anesthetized sheep, *J. Physiol. Sci.* 62 (2012) 21–28.
- [131] Y. Furuno, Y. Nagamoto, M. Fujita, T. Kaku, S. Sakurai, A. Kuroiwa, Reflection as a cause of mid-systolic deceleration of pulmonary flow wave in dogs with acute pulmonary hypertension: comparison of pulmonary artery constriction with pulmonary embolisation, *Cardiovasc Res.* 25 (1991) 118–124.
- [132] J.C. Grignola, F. Ginés, D. Bia, R. Armentano, Improved right ventricular-vascular coupling during active pulmonary hypertension, *Int. J. Cardiol.* 115 (2007) 171–182.
- [133] W.K. Laskey, V.A. Ferrari, H.I. Palevsky, W.G. Kussmaul, Pulmonary artery hemodynamics in primary pulmonary hypertension, *J. Am. Coll. Cardiol.* 21 (1993) 406–412.
- [134] Y. Ben-Shlomo, M. Spears, C. Boustred, M. May, S.G. Anderson, E.J. Benjamin, et al., Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects, *J. Am. Coll. Cardiol.* 63 (7) (2014) 636–646.
- [135] R. Asmar, A. Benetos, J. Topouchian, P. Laurent, B. Pannier, A.M. Brisac, et al., Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies, *Hypertension* 26 (1995) 485–490.
- [136] J.J. Van der Heijden-Spek, J.A. Staessen, R.H. Fagard, A.P. Hoeks, H.A. Boudier, L.M. van Bortel, Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study, *Hypertension* 35 (2000) 637–642.
- [137] K. Cruickshank, L. Riste, S.G. Anderson, J.S. Wright, G. Dunn, R.G. Gosling, Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? *Circulation* 106 (2002) 2085–2090.
- [138] W.M. Bradlow, P.D. Gatehouse, R.L. Hughes, A.B. O'Brien, J.S.R. Gibbs, D.N. Firmin, et al., Assessing normal pulse wave velocity in the proximal pulmonary arteries using transit time: a feasibility, repeatability, and observer reproducibility study by cardiovascular magnetic resonance, *J. Magn. Reson Imaging* 25 (2007) 974–981.
- [139] J.J.M. Westenberg, E.P. van Poelgeest, P. Steendijk, H.B. Grotenhuis, J.W. Jukema, A. de Roos, Bramwell-Hill modeling for local aortic pulse wave velocity estimation: a validation study with velocity-encoded cardiovascular magnetic resonance and invasive pressure assessment, *J. Cardiovasc Magn. Reson* 14 (2012) 2.
- [140] L. Joly, C. Perret-Guillaume, A. Kearney-Schwartz, P. Salvi, D. Mandry, P.-Y. Marie, et al., Pulse wave velocity assessment by external noninvasive devices and phase-contrast magnetic resonance imaging in the obese, *Hypertension* 54 (2009) 421–426.
- [141] A. Dogui, N. Kachenoura, F. Frouin, M. Lefort, A. De Cesare, E. Mousseaux, et al., Consistency of aortic distensibility and pulse wave velocity estimates with respect to the Bramwell-Hill theoretical model: a cardiovascular magnetic resonance study, *J. Cardiovasc Magn. Reson* 13 (2011) 11.
- [142] H.-H. Peng, H.-W. Chung, H.-Y. Yu, W.-Y.I. Tseng, Estimation of pulse wave velocity in main pulmonary artery with phase contrast MRI: preliminary investigation, *J. Magn. Reson Imaging* 24 (2006) 1303–1310.
- [143] E.-S.H. Ibrahim, J.M. Shaffer, R.D. White, Assessment of pulmonary artery stiffness using velocity-encoding magnetic resonance imaging: evaluation of techniques, *Magn. Reson Imaging* 29 (2011) 966–974.
- [144] I. Blanco, E. Gimeno, P.A. Munoz, S. Pizarro, C. Gistau, R. Rodriguez-Roisin, et al., Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension, *Am. J. Respir. Crit. Care Med.* 181 (2010) 270–278.
- [145] I. Blanco, S. Santos, J. Gea, R. Güell, F. Torres, E. Gimeno-Santos, et al., Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial, *Eur. Respir. J.* 42 (2013) 982–992.
- [146] D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, et al., A randomised, controlled trial of bosentan in severe COPD, *Eur. Respir. J.* 32 (2008) 619–628.
- [147] D.B. Badesch, J. Feldman, A. Keogh, M.A. Mathier, R.J. Oudiz, S. Shapiro, et al., ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension, *Cardiovasc Ther.* 30 (2012) 93–99.
- [148] A.R. Goudie, B.J. Lipworth, P.J. Hopkinson, L. Wei, A.D. Struthers, Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial, *Lancet Respir. Med.* 2 (2014) 293–300.
- [149] K. Toyama, S. Sugiyama, H. Oka, Y. Iwasaki, H. Sumida, T. Tanaka, et al., Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease, *PLoS One* 7 (2012) e41369.
- [150] E.C. Rizos, A.P. Agouridis, M.S. Elisaf, The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review, *Curr. Vasc. Pharmacol.* 8 (2010) 638–644.
- [151] J.L. Wright, S. Zhou, O. Preobrazhenska, C. Marshall, D.D. Sin, I. Laher, et al., Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling, *Am. J. Respir. Crit. Care Med.* 183 (2011) 50–58.

- [152] J.-H. Lee, D.-S. Lee, E.-K. Kim, K.-H. Choe, Y.-M. Oh, T.-S. Shim, et al., Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs, *Am. J. Respir. Crit. Care Med.* 172 (2005) 987–993.
- [153] R.M. Reed, A. Iacono, A. DeFilippis, S. Jones, M. Eberlein, N. Lechtzin, et al., Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD, *COPD* 8 (2011) 96–102.
- [154] S. Janda, K. Park, J.M. Fitzgerald, M. Etminan, J. Swiston, Statins in COPD: a systematic review, *Chest* 136 (2009) 734–743.
- [155] C.M.M. Lawes, S. Thornley, R. Young, R. Hopkins, R. Marshall, W.C. Chan, et al., Statin use in COPD patients is associated with a reduction in mortality: a national cohort study, *Prim. Care Respir. J.* 21 (2012) 35–40.
- [156] T.-M. Lee, M.-S. Lin, N.-C. Chang, Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin, *Am. J. Cardiol.* 101 (2008) 530–535.
- [157] L. Mascitelli, F. Pezzetta, M.R. Goldstein, Statins, vitamin D, and COPD, *Chest* 137 (2010) 742–743 author reply 743.
- [158] M. Pearson, Statins for COPD: a challenge to conventional beliefs? *Prim. Care Respir. J.* 21 (2012) 5–7.
- [159] H.G. Bogren, R.H. Klipstein, R.H. Mohiaddin, D.N. Firmin, S.R. Underwood, R.S. Rees, et al., Pulmonary artery distensibility and blood flow patterns: a magnetic resonance study of normal subjects and of patients with pulmonary arterial hypertension, *Am. Heart J.* 118 (1989) 990–999.
- [160] R. Paz, R.H. Mohiaddin, D.B. Longmore, Magnetic resonance assessment of the pulmonary arterial trunk anatomy, flow, pulsatility and distensibility, *Eur. Heart J.* 14 (1993) 1524–1530.
- [161] G.R. Stevens, A. Lala, J. Sanz, M.J. Garcia, V. Fuster, S. Pinney, Exercise performance in patients with pulmonary hypertension linked to cardiac magnetic resonance measures, *J. Heart Lung Transpl.* 28 (2009) 899–905.
- [162] M.-P. Revel, J.-B. Faivre, M. Remy-Jardin, V. Delannoy-Deken, A. Duhamel, J. Remy, Pulmonary hypertension: ECG-gated 64-section CT angiographic evaluation of new functional parameters as diagnostic criteria, *Radiology* 250 (2009) 558–566.
- [163] M.P. Kao, D.S. Ang, S.J. Gandy, M.A. Nadir, J.G. Houston, C.C. Lang, et al., Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease, *J. Am. Soc. Nephrol.* 22 (2011) 1382–1389.
- [164] K. Kostka-Jeziorny, P. Uruski, A. Tykarski, Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients, *Blood Press* 20 (2011) 104–110.
- [165] F. Khan, J. George, K. Wong, S. McSwiggan, A.D. Struthers, J.J.F. Belch, Allopurinol treatment reduces arterial wave reflection in stroke survivors, *Cardiovasc Ther.* 26 (2008) 247–252.
- [166] R. Butler, A.D. Morris, J.J.F. Belch, A. Hill, A.D. Struthers, Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension, *Hypertension* 35 (2000) 746–751.
- [167] C. Cardillo, C.M. Kilcoyne, R.O. Cannon, A.A. Quyyumi, J.A. Panza, Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients, *Hypertension* 30 (1997) 57–63.
- [168] S. Guthikonda, xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers, *Circulation* 107 (2003) 416–421.
- [169] S. Guthikonda, K. Woods, C.A. Sinkey, W.G. Haynes, Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers, *Am. J. Cardiol.* 93 (2004) 664–668.
- [170] a a El Solh, R. Saliba, T. Bosinski, B.J.B. Grant, E. Berbary, N. Miller, Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study, *Eur. Respir. J.* 27 (2006) 997–1002.
- [171] B. Sharma, T.G. Neilan, R.Y. Kwong, D. Mandry, R.L. Owens, D. McSharry, et al., Evaluation of right ventricular remodeling using cardiac magnetic resonance imaging in co-existent chronic obstructive pulmonary disease and obstructive sleep apnea, *COPD* 10 (2013) 4–10.
- [172] Y. Hoshikawa, S. Ono, S. Suzuki, T. Tanita, M. Chida, C. Song, et al., Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia, *J. Appl. Physiol.* 90 (2001) 1299–1306.
- [173] R.P. Jankov, C. Kantores, J. Pan, J. Belik, Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats, *Am. J. Physiol. Lung Cell. Mol. Physiol.* 294 (2008) L233–L245.
- [174] J.M. Dopp, N.R. Philippi, N.J. Marcus, E.B. Olson, C.E. Bird, J.J.M. Moran, et al., Xanthine oxidase inhibition attenuates endothelial dysfunction caused by chronic intermittent hypoxia in rats, *Respiration* 82 (2011) 458–467.
- [175] A.L. Williams, L. Chen, S.M. Scharf, Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia, *Sleep. Breath.* 14 (2010) 51–57.
- [176] J. Kjaeve, T. Veel, L. Bjertnaes, Allopurinol inhibits hypoxic pulmonary vasoconstriction. Role of toxic oxygen metabolites, *Acta Anaesthesiol. Scand.* 34 (1990) 384–388.
- [177] M. Ichinose, H. Sugiura, S. Yamagata, A. Koarai, M. Tomaki, H. Ogawa, et al., Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways, *Eur. Respir. J.* 22 (2003) 457–461.
- [178] Y. Takeda, I. Miyamori, T. Yoneda, H. Hatakeyama, S. Inaba, K. Furukawa, et al., Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin, *J. Clin. Endocrinol. Metab.* 81 (1996) 2797–2800.
- [179] J. Davies, A. Gavin, M. Band, A. Morris, A. Struthers, Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients, *Br. J. Clin. Pharmacol.* 59 (2005) 520–523.
- [180] N.C. Edwards, R.P. Steeds, P.M. Stewart, C.J. Ferro, J.N. Townend, Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial, *J. Am. Coll. Cardiol.* 54 (2009) 505–512.
- [181] B.A. Maron, Y.-Y. Zhang, K. White, S.Y. Chan, D.E. Handy, C.E. Mahoney, et al., Aldosterone Inactivates the Endothelin-B Receptor via a CysteinyI Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension, *Circulation* 126 (2012) 963–974.
- [182] J.M. Elinoff, J.E. Rame, P.R. Forfia, M.K. Hall, J. Sun, A.M. Gharib, et al., A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial, *Trials* 14 (2013) 91.
- [183] R.M. Timms, F.U. Khaja, G.W. Williams, Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease, *Ann. Intern. Med.* 102 (1985) 29–36.
- [184] M.N. Bartels, S. Jelic, R.C. Basner, P. Ngai, J.M. Gonzalez, R.E. De Meersman, Supplemental oxygen increases arterial stiffness in chronic obstructive pulmonary disease, *Respir. Med.* 98 (2004) 84–89.
- [185] S.J. Ziemann, V. Melenovsky, D.A. Kass, Mechanisms, pathophysiology, and therapy of arterial stiffness, *Arterioscler. Thromb. Vasc. Biol.* 25 (2005) 932–943.